Watkins, Lance;
Reuber, Markus;
Perera, Bhathika;
Courtenay, Ken;
Banks, Roger;
Murphy, Emma;
Angus-Leppan, Heather;
(2021)
Valproate prescribing practices for women with intellectual disability across Europe.
Acta Neurologica Scandinavica
, 143
(1)
pp. 56-61.
10.1111/ane.13337.
Preview |
Text
Valproate prescribing practices for women with intellectual disability.pdf - Published Version Download (458kB) | Preview |
Abstract
BACKGROUND: Valproate (VPA) is a known teratogen associated with greater risk of major congenital malformations and other neurodevelopmental sequelae than all other licensed antiepileptic medicines. To reduce the potential for VPA-related teratogenicity, the European Medicines Agency issued recommendations in 2018. Over two-thirds of women/girls with intellectual disability (ID) may have treatment-resistant epilepsy that could benefit from VPA treatment. AIMS: This investigation compared VPA prescribing practice for women/girls with ID between European countries, specifically evaluating the practice in the UK with that in other countries. METHODS: An expert working group with representation from key stake-holding organizations developed a survey for dissemination to relevant professionals across Europe. RESULTS: Seventy one responses were received (27 UK, 44 Europe). Clinicians in the UK were more likely to report that they are working to mandatory regulations compared with European respondents (P = .015). European respondents were less likely to be aware of user-independent contraception options (P = .06). In The UK, VPA regulations were more likely to be applied to women with ID than in Europe (P = .024). CONCLUSION: There is heterogeneity in the application of VPA regulations across Europe for women/girls with ID. In both the UK and Europe, the regulations lack suitable adjustments for specific ID-related factors.
| Type: | Article |
|---|---|
| Title: | Valproate prescribing practices for women with intellectual disability across Europe |
| Location: | Denmark |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/ane.13337 |
| Publisher version: | https://doi.org/10.1111/ane.13337 |
| Language: | English |
| Additional information: | © 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| Keywords: | Intellectual disability, pregnancy, regulatory guidance, teratogenicity, valproate |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry > Epidemiology and Applied Clinical Research |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10169609 |
Archive Staff Only
 |
View Item |
